HK1177889A1 - Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent cdc7 - Google Patents

Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent cdc7

Info

Publication number
HK1177889A1
HK1177889A1 HK13104963.0A HK13104963A HK1177889A1 HK 1177889 A1 HK1177889 A1 HK 1177889A1 HK 13104963 A HK13104963 A HK 13104963A HK 1177889 A1 HK1177889 A1 HK 1177889A1
Authority
HK
Hong Kong
Prior art keywords
cdc7
antineoplastic agent
therapeutic combination
inhibitor
cdc7 inhibitor
Prior art date
Application number
HK13104963.0A
Other languages
English (en)
Chinese (zh)
Inventor
．巴裡納利
．希亞沃雷拉
．派森蒂
．蒙塔尼奧利
Original Assignee
內爾維阿諾醫學科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 內爾維阿諾醫學科學有限公司 filed Critical 內爾維阿諾醫學科學有限公司
Publication of HK1177889A1 publication Critical patent/HK1177889A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK13104963.0A 2009-11-18 2013-04-24 Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent cdc7 HK1177889A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09176370 2009-11-18
PCT/EP2010/067675 WO2011061222A1 (fr) 2009-11-18 2010-11-17 Combinaison thérapeutique comprenant un inhibiteur de cdc7 et un agent antinéoplasique

Publications (1)

Publication Number Publication Date
HK1177889A1 true HK1177889A1 (en) 2013-08-30

Family

ID=43501061

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13104963.0A HK1177889A1 (en) 2009-11-18 2013-04-24 Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent cdc7

Country Status (9)

Country Link
US (1) US9119877B2 (fr)
EP (1) EP2501385B1 (fr)
JP (1) JP2013511487A (fr)
CN (1) CN102753176B (fr)
AR (1) AR079049A1 (fr)
ES (1) ES2625492T3 (fr)
HK (1) HK1177889A1 (fr)
TW (1) TW201127384A (fr)
WO (1) WO2011061222A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48140E1 (en) 2011-03-31 2020-08-04 Carna Biosciences, Inc. Furanone derivative
EP2736514B1 (fr) * 2011-07-28 2017-10-18 Nerviano Medical Sciences S.r.l. Pyrimidinyl-pyrroles substitués alcynyle agissant comme inhibiteurs de kinase
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
WO2015115355A1 (fr) 2014-01-31 2015-08-06 カルナバイオサイエンス株式会社 Composition d'agent anticancéreux
WO2019165473A1 (fr) * 2018-02-26 2019-08-29 Sierra Oncology, Inc Procédés de traitement du cancer comprenant des inhibiteurs de cdc7
GB201807147D0 (en) * 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750737A (en) * 1996-09-25 1998-05-12 Sisti; Nicholas J. Method for paclitaxel synthesis
ZA200808966B (en) * 2006-03-27 2010-03-31 Nerviano Medical Sciences Srl Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
TWI426074B (zh) 2008-04-30 2014-02-11 Nerviano Medical Sciences Srl ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法

Also Published As

Publication number Publication date
TW201127384A (en) 2011-08-16
JP2013511487A (ja) 2013-04-04
CN102753176A (zh) 2012-10-24
EP2501385A1 (fr) 2012-09-26
ES2625492T3 (es) 2017-07-19
US20120276093A1 (en) 2012-11-01
CN102753176B (zh) 2014-07-16
WO2011061222A1 (fr) 2011-05-26
US9119877B2 (en) 2015-09-01
AR079049A1 (es) 2011-12-21
EP2501385B1 (fr) 2017-03-01

Similar Documents

Publication Publication Date Title
HK1154343A1 (en) Therapeutic combination comprising a cdks inhibitor and an antineoplastic agent
HK1177889A1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent cdc7
SI2185198T1 (sl) Inhibitorji LOX in LOXL2 ter njihova uporaba
IL209477A (en) Pyrrolidine derivatives as 2-metap inhibitors and their pharmacological preparations
HK1161583A1 (en) Deacetylase inhibitors and uses thereof
IL212915A (en) Medical combination containing 90 hsp inhibitor and mtor inhibitor
GB0908957D0 (en) Therapeutic agents
ZA200904860B (en) Combination therapy with angiogenesis inhibitors
GB0803018D0 (en) Therapeutic compounds and their use
EP2192178A4 (fr) Inhibiteur de la b-glucuronidase
GB0804685D0 (en) Therapeutic compounds and their use
IL213974A0 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
GB0807609D0 (en) Therapeutic compounds and their use
EP2268281A4 (fr) Thiénopyrroles et pyrrolothiazoles utilisés comme nouveaux agents thérapeutiques
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
IL208771A0 (en) Iminopyridine derivatives and use thereof
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB201211237D0 (en) CDK5 inhibitors and therapeutic uses thereof
GB0900484D0 (en) Therapeutic agent
HK1170277A1 (en) Medicinal agent case
GB0812913D0 (en) Therapeutic compounds and their use
GB0917927D0 (en) Ido inhibitors and therapeutic uses thereof
EP2140876A4 (fr) Agent thérapeutique comprenant de la vasohibine
AP2788A (en) Simalikalactone E and use thereof as a medicament
EP2274294A4 (fr) 5-diméthoxy fumagillol et ses dérivés

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231119